Molecular Formula | C26H22N4O3 |
Molar Mass | 438.48 |
Density | 1.32±0.1 g/cm3(Predicted) |
Melting Point | >270°C (dec.) |
Boling Point | 683.3±55.0 °C(Predicted) |
Solubility | DMSO (Slightly, Heated) |
Appearance | Solid |
Color | White to Off-White |
pKa | 3.68±0.10(Predicted) |
Storage Condition | -20°C Freezer |
In vitro study | In one group of cultured cells, treatment with PLX51107 administered for a short period of time (4 hours) resulted in a sharp down-regulation of c-Myc levels, but did not immediately elicit an apoptotic response. PLX51107 induced apoptosis after prolonged treatment time (continuous culture of 16 hours or longer). PLX51107 can cause accumulation of p21 and IκBα, decrease cMYC levels, and regulate the expression of pro-and anti-apoptotic proteins. |
In vivo study | PLX51107 was well tolerated in mice. In rodents and dogs, PLX51107 has a relatively short half-life of less than 3 hours. PLX51107 has anti-tumor activity in preclinical animal models of chronic lymphocytic leukemia and aggressive lymphoma. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.281 ml | 11.403 ml | 22.806 ml |
5 mM | 0.456 ml | 2.281 ml | 4.561 ml |
10 mM | 0.228 ml | 1.14 ml | 2.281 ml |
5 mM | 0.046 ml | 0.228 ml | 0.456 ml |